ViroPharma Reports Encouraging Data – Zacks.com
ViroPharma Reports Encouraging Data Zacks.com ... dosed with Plenadren once daily experienced a better circadian-based serum cortisol profile, lower body weight, lower blood pressure, and improved glucose metabolism, compared to treatment with immediate release hydrocortisone thrice daily. |
Topical Cyclosporine Proves Beneficial For Ocular Rosacea – Skin and Allergy News Digital Network
 Skin and Allergy News Digital Network | Topical Cyclosporine Proves Beneficial For Ocular Rosacea Skin and Allergy News Digital Network WAIKOLOA, HAWAII – Topical cyclosporine 0.05% ophthalmic emulsion significantly outperformed artificial tears for the treatment of ocular rosacea in a double-blind, randomized, multicenter study. "It's a fairly small study, but I think it gives us some ... |
Resolute zotarolimus stent approved in US – TheHeart.Org
Resolute zotarolimus stent approved in US TheHeart.Org The Resolute DES has shown similar safety and efficacy to the Xience V everolimus-eluting stent (Abbott), the market-leader in the US, in two randomized controlled trials (RESOLUTE "all-comers" and TWENTE). The results of TWENTE were presented at TCT ... |
Psoriasis Therapy: Don’t Forget About the Classics – Skin and Allergy News Digital Network
 Skin and Allergy News Digital Network | Psoriasis Therapy: Don't Forget About the Classics Skin and Allergy News Digital Network "Cyclosporine is an indispensable therapy in my clinic," said Dr. Sobell. He said that he uses it mostly for psoriasis in crisis situations, but also as a transitional therapy. "Clinicians have concerns about potential nephrotoxicity, but at low doses ... |
Screening for adrenal suppression in children lacks standard approach – Endocrine Today
 Endocrine Today | Screening for adrenal suppression in children lacks standard approach Endocrine Today Screening for adrenal suppression in pediatric patients assigned inhaled corticosteroids for asthma can identify adrenal insufficiency and help prevent adrenal crises. However, there is no consensus regarding the efficacy and practicality of various ... |
2nd-Gen Stents Square Off – MedPage Today
 Forbes | 2nd-Gen Stents Square Off MedPage Today The investigational Resolute zotarolimus-eluting stent proved noninferior to the everolimus-eluting Xience regarding target vessel failure. The overall rate of definite/probable stent thrombosis was low among the two groups, with no statistical ... TWENTE Published: New Medtronic Resolute Heart Stent Matches Abbott's Xience |
Abbott’s Architect tacrolimus assay shows medication monitoring benefits – Zenopa
Abbott's Architect tacrolimus assay shows medication monitoring benefits Zenopa Abbott has published data from a new clinical study that showcases the benefits of its Architect tacrolimus assay in offering accurate medication monitoring following solid organ transplantations. The device offers a standardised method of assessing ... |
REVA Medical: patient enrolment underway in Europe for pilot trial of coronary … – Proactive Investors Australia
 Proactive Investors Australia | REVA Medical: patient enrolment underway in Europe for pilot trial of coronary ... Proactive Investors Australia REVA Medical (ASX: RVA) has begun enrolling patients in Europe in a pilot study of its ReZolve™ sirolimus-eluting bioresorbable coronary scaffold to treat blockages caused by coronary artery disease. The RESTORE trial is evaluating the safety and ... |
What treatments work for sciatica? – WebMD.Boots.com
What treatments work for sciatica? WebMD.Boots.com Anti-inflammation drugs called corticosteroids and a muscle relaxing drug called gabapentin appear to be the treatments that are most likely to work for people with sciatica, according to a new review of studies. By Lilian Anekwe Sciatica is a common ... |
Topical Corticosteroids Impair Restoration of Skin Barrier – MD News (press release)
 MD News (press release) | Topical Corticosteroids Impair Restoration of Skin Barrier MD News (press release) Topical corticosteroids offer a more potent anti-inflammatory effect for the treatment of atopic dermatitis, but they may impair the restoration of the skin barrier and can induce skin atrophy, making topical calcineurin inhibitors more suitable for ... |